GenSight Biologics Announces the Filing of its 2018 Universal Registration Document

GenSight Biologics obtains €15 million in financing through a bond issuance from Kreos Capital and a reserved capital increase from Sofinnova and 3SBio

GenSight Biologics Reports its Cash Position as of September 30, 2019 and Provides Operational Update

GenSight Biologics integrates the Enternext® PEA-PME 150 index by Euronext

GenSight Biologics Reports Interim Financial Results for the First Half of 2019 and Provides Operational Update

GenSight Biologics Reports Full Year 2018 Financial Results

GenSight Biologics Reports its Cash Position as of March 31, 2019

GenSight Biologics completes a capital increase of €8 million without discount subscribed entirely by Sofinnova

GenSight Biologics Updates its 2019 Financial Calendar

GenSight Biologics Announces its 2019 Financial Calendar